设为首页|English Version
当前位置: 首页 >> 师资队伍
教师内容页
姚煜  
研究领域(方向)
近年来从事肿瘤侵袭转移与肿瘤耐药的基础与临床研究。
个人及工作简历

姚煜,5822yh银河国际毕业,博士学位,主任医师,博士生导师,现任5822yh银河国际第一附属医院肿瘤内科主任、党支部书记。

19936月于西北民族大学医学院获临床医学学士学位,19997月于5822yh银河国际获肿瘤学硕士学位,20089月于5822yh银河国际获内科学博士学位。19936月至今于5822yh银河国际第一附属医院肿瘤内科工作,20161月晋升主任医师,现任肿瘤内科副主任、党支部书记。

目前担任中国临床肿瘤学会(CSCO)理事、国家肿瘤质控中心肺癌质控专家委员会委员、中华医学会肿瘤康复支持治疗学组副组长、中国医药教育协会肿瘤转移专委会副主委、中国医药教育协会肿瘤化学治疗专业委员会副主委、中国抗肿瘤药物临床应用监测专家委会委员、CSCO恶性黑色素瘤专业委员会常委、CSCO肺癌专业委员会委员、吴阶平肿瘤多学科诊疗委员会常委、中国医药协会肿瘤免疫治疗专家委员会委员、陕西省抗癌协会常务理事、陕西省抗癌协会化疗专业委员会主任委员、中华医学会西安医学会肿瘤学分会主任委员、陕西省抗癌协会老年肿瘤专业委员会副主委、陕西省抗癌协会中西整合肿瘤专业委员会副主委、陕西省抗癌协会肿瘤标志物专业委员会副主委、陕西医学会肿瘤内科专业委员会常委、陕西省抗癌协会抗癌药物专业委员常委、陕西省药物临床(GCP)和研发机构专家、西安市抗癌学会秘书长、JCO中文编委。荣获2018年陕西省抗癌协会优秀论文一等奖、2022年“陕西省五一巾帼标兵”。

科研项目

主持国家自然科学基金专项项目1项、陕西省科技创新团队1项、陕西省高校联合项目1项、陕西省科技攻关项目1项,陕西省国际科技合作重点项目4项,陕西省国际合作项目1项,吴阶平基金1项,5822yh银河国际学科综合交叉类科研项目1项,5822yh银河国际研究生教育改革项目1项;作为第二参与人参与国家自然科学基金2项;获得国家发明专利1项。

学术及科研成果、专利、论文

课题:

[1] 协同拮抗HDM2/HDMX激活p53的自组装镜像微蛋白靶向治疗视网膜母细胞瘤的作用研究。国家自然科学基金专项项目。编号:82141126。2022.01-2024.12,在研。

[2] 基于精准医学的肺癌免疫治疗研究与临床应用创新团队。陕西省科技创新团队。编号:2021TD-44,2021-2024,在研;

[3] 纳米工程化D型微蛋白靶向MDM2与MDMX的肺癌治疗与免疫治疗增敏研究。陕西省高校联合项目一般项目。编号:2020GXLH-Y-020,2020-2022,在研;

[4] 循环肿瘤DNA预测阿美替尼疗效的研究。蕙兰-豪森肺癌精准科研基金。编号:HL-HS2020-124,2020-2022,在研,5万元,主持;

[5] METTL3通过m6A修饰PTEN诱导肺癌免疫微环境的作用及机制研究。希思科-恒瑞肿瘤研究基金。编号:Y-HR2019-0401,2020-2022,在研,主持;

[6] microRNA-155通过增强外泌体分泌促进非小细胞肺癌转移前微环境形成。陕西省国际合作项目。编号:2019KW-074,2019-2022,在研;

[7] 获得性EGFR-TKIs耐药患者血清ctDNA的检测。吴阶平基金,编号:50603020,项目主持,2015-2017,在研;

[8] MicroRNA 32在肝细胞癌多激酶受体抑制剂耐药中的作用及机制研究。陕西省国际合作项目。编号:2016KW-017,2015-2018,完成;

[9] 程序解离型纳米载体制备与阿霉素-siRNA协同抗癌研究。5822yh银河国际学科综合交叉类科研项目,编号:xjj2013130,项目主持,2013.1-2015.12,完成;

[10] SOCS4在乳腺癌细胞株中的表达和对乳腺癌细胞恶性增殖的影响及其可能的作用机制。陕西省科技攻关项目,编号:2013K12-12-03,项目主持,2013-2015,完成;

[11] MicroRNA-638对胃癌细胞STARD 10表达与功能的调控机制。陕西省国际科技合作重点项目, 编号2010kw-17,项目主持,2010-2012,完成;

[12] 胃癌发生相关miRNA的筛选与功能鉴定研究,陕西省国际科技合作重点项目,编号:2009kw-18,项目主持,2009-2010,完成;

[13] 易瑞沙抗胃癌作用机制的研究。陕西省科技攻关项目, 编号:2006K 09-G6-(1),项目主持,2006-2009,完成;

[14] PTENP1作为ceRNA调控PTEN表达及介导肝癌EGFR抑制剂耐药的机制研究,国家自然科学基金,编号:81301909,第二参与人,2014.1-2016.12,完成;

[15] LKB1通过调控sestrin2影响肺癌细胞自噬活性的机制研究。国家自然科学基金,编号:81101777,第二参与人,2012.1-2014.12,完成。

 

先后发表第一或通讯作者SCI文章30余篇:

(1)     Yao Y, Yu Z, Ma Y, Ou Q, Wu X, Lu D, Li X. Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes. ESMO Open. 2022 Mar 16;7(2):100405.

(2)     Jiang A, Shi X, Zheng H, Liu N, Chen S, Gao H, Ren M, Zheng X, Fu X, Liang X, Ruan Z, Tian T, Yao Y. Establishment and validation of a nomogram to predict the in-hospital death risk of nosocomial infections in cancer patients. Antimicrob Resist Infect Control. 2022 Feb 7;11(1):29.

(3)     Jiang A, Wang J, Liu N, Zheng X, Li Y, Ma Y, Zheng H, Chen X, Fan C, Zhang R, Fu X, Yao Y. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Data to Establish and Validate a Prognostic Model for Patients With Lung Adenocarcinoma. Front Genet. 2022 Jan 27;13:833797.

(4)     Zheng X, Yan J, You W, Li F, Diao J, He W, Yao Y. De Novo Nano-Erythrocyte Structurally Braced by Biomimetic Au(I)-peptide Skeleton for MDM2/MDMX Predation toward Augmented Pulmonary Adenocarcinoma Immunotherapy. Small. 2021 May;17(20):e2100394.

(5)     Jiang A, Liu N, Zhao R, Liu S, Gao H, Wang J, Zheng X, Ren M, Fu X, Liang X, Tian T, Ruan Z, Yao Y. Construction and Validation of a Novel Nomogram to Predict the Overall Survival of Patients With Combined Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study. Cancer Control. 2021 Jan-Dec;28:10732748211051228.

(6)     Jiang A, Liu N, Bai S, Wang J, Gao H, Zheng X, Fu X, Ren M, Zhang X, Tian T, Ruan Z, Liang X, Yao Y: Identification and validation of an autophagy-related long non-coding RNA signature as a prognostic biomarker for patients with lung adenocarcinoma. Journal of Thoracic Disease 2021, 13(2):720-734.

(7)     Jiang AM, Zheng HR, Liu N, Zhao R, Ma YY, Bai SH, Tian T, Liang X, Ruan ZP, Fu X, Yao Y. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis. Cancer Control. 2021 Jan-Dec;28:10732748211050581.

(8)     Liu N, Jiang A, Zheng X, Fu X, Zheng H, Gao H, Wang J, Liang X, Tian T, Ruan Z, Yao Y. Prognostic Nutritional Index identifies risk of early progression and survival outcomes in Advanced Non-small Cell Lung Cancer patients treated with PD-1 inhibitors. J Cancer. 2021 Mar 15;12(10):2960-2967.

(9)     Gao H, Tian T, Li S, Zhang Y, Fu X, Zheng X, Liu N, Jiang A, Ren M, Zhang X, Liang X, Ruan Z, Geng Z, Yao Y: Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study. Cancer Management and Research 2021, 13:889-898

(10) Jiang A, Ren M, Liu N, Gao H, Wang J, Zheng X, Fu X, Liang X, Ruan Z, Tian T, Yao Y: Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. International Journal of Medical Sciences 2021

(11) Zhang Y*, Yao Y*, Xu Y*, Li L, Gong Y, Zhang K, Zhang M, Guan Y, Chang L, Xia X, Li L, Jia S, Zeng Q. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. Nat Commun. 2021 Jan 4;12(1):11.

(12) Jiang A, Liu N, Zhao R, Zheng Ha, Chen X, Fan C, Zhang R, Zheng X, Fu X, Yao Y, Tian T: Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis. Annals of Clinical Microbiology and Antimicrobials 2020, 19(1)

(13) Jiang A, Shi X, Liu N, Gao H, Ren M, Zheng X, Fu X, Liang X, Ruan Z, Yao Y, Tian T: Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China. Bmc Infectious Diseases 2020, 20(1).

(14) Jiang A, Liu N, Said R, Ren M, Gao Huan, Zheng X, Fu X, Liang X, Ruan Z, Yao Y, Tian T: Nosocomial Infections in Gastrointestinal Cancer Patients: Bacterial Profile, Antibiotic Resistance Pattern, and Prognostic Factors. Cancer Management and Research 2020, 12:4969-4979.   

(15) Jiang A, Zhao R, Liu N, Ma Y, Ren M, Tian T*, Yao Y*: The prognostic value of pretreatment prognostic nutritional index in patients with small cell lung cancer and it's influencing factors: a meta-analysis of observational studies. Journal of Thoracic Disease 2020, 12(10):5718-5728.

(16) Jiang A. M., Liu N., Bai S. H., Wang J. J., Gao H., Zheng X. Q., Fu X. A., Ren M. D., Zhang X. N., Tian T., Ruan Z. P., Yao Y., Liang X. A.: The Construction and Analysis of Tumor-Infiltrating Immune Cells and ceRNA Networks in Bladder Cancer. Front Genet 2020, 11:15.

(17) Li, S.N. Ma, J.Q. Zheng, Q. Zhai, Y. Zhou, J. Liao, Z.J. Yao, Y.. (2020). Microrna-638 inhibited cell proliferation by targeting cdk2. Acta Medica Mediterranea. 36. 2839-2844. 10.19193/0393-6384_2020_5_434.

(18) Yan J, Yao Y, Yan S, Gao R, Lu W, He W. Chiral Protein Supraparticles for Tumor Suppression and Synergistic Immunotherapy: An Enabling Strategy for Bioactive Supramolecular Chirality Construction. Nano Lett. 2020;20(8):5844-5852. PMID: 32589431. IF: 11.238.

(19) Zhao Z, Fu T, Gao J, Yao Y, et al. Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors [published online ahead of print, 2020 Apr 13]. J Med Genet. 2020;jmedgenet-2019-106546. PMID: 32284345. IF: 4.943.

(20) Peng H, Lu L, Zhou Z, Yao Y, et al. CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients. Genes (Basel). 2019;10(11):926. PMID: 31739500. IF: 3.759.

(21) Fu X, Liu Z, Xiang L, Liu M, Zheng X, Wang J, Liu N, Gao H, Jiang A, Yang Y, Liang X, Ruan Z, Tian T, Yao Y. PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer. Cancer Manag Res. 2020 Oct 30;12:10939-10948.

(22) Liu N, Wang J, Fu X, Zheng X, Gao H, Tian T, Ruan Z, Yao Y. A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement. Cancer Biol Ther. 2020;21(1):12-16. PMID: 31559892. IF: 3.659

(23) Fu X, Liu M, Qu S, Ma J, Zhang Y, Shi T, Wen H, Yang Y, Wang S, Wang J, Nan K, Yao Y#, Tian T#. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. J Exp Clin Cancer Res. 2018 Mar 12;37(1):52. PMID: 29530052. IF: 5.646.

(24)     Fu X, Wen H, Jing L, Yang Y, Wang W, Liang X, Nan K, Yao Y#, Tian T#.MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Sci. 2017 Apr;108(4):620-631. PMID: 28132399. IF: 4.751.

(25) Yao Y, Liu J, Li L, Yuan Y, Nan K, Wu X, Zhang Z, Wu Y, Li X, Zhu J, Meng X, Wei L, Chen J, Jiang Z. Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer. Oncotarget. 2017 Jan 10;8(2):2130-2140.

(26) Wang MC, Liang X, Liu ZY, Cui J, Liu Y, Jing L, Jiang LL, Ma JQ, Han LL, Guo QQ, Yang CC, Wang J,Wu T, Nan KJ, Yao Y. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines. Oncol Rep. 2015 Jan;33(1):239-49

(27) Xiongwei Huo, Suoni Li, Tingting Shi, Aili Suo, Zhiping Ruan, Yu Yao. Tripartite motif 16 inhibits epithelial-mesenchymal transition and metastasis by down-regulating sonic hedgehog pathway in non-small cell lung cancer cells. Biochem Biophys Res Commun. 2015 May 15;460(4)

(28) Li XY, Yao X, Li SN, Suo AL, Ruan ZP, Liang X, Kong Y, Zhang WG, Yao Y. RNA-Seq profiling reveals aberrant RNA splicing in patient with adult acute myeloid leukemia during treatment. Eur Rev Med Pharmacol Sci. 2014;18(9):1426-33.

(29) Wang Y, Yao X, Li SN, Suo AL, Tian T, Ruan ZP, Guo H, Yao Y. Detection of prostate cancer related copy number variations with SNP genotyping array. Eur Rev Med Pharmacol Sci. 2013 Nov;17(21):2916-22.

(30) Hu TH*, Yao Y*, Yu S, Han LL, Wang WJ, Guo H, Tian T, Ruan ZP, Kang XM, Wang J, Wang SH, Nan KJ. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway. Cancer Lett. 2014 Nov 28;354(2):417-26.

(31) Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C. MicroRNA profiling of human gastric cancer. Molecular Medicine Reports, 2009, 2(6): 963-970.

(32) Yao Y, Huang C, Li ZF, Wang AY, Liu LY, Zhao XG, Luo Y, Ni L, Zhang WG, Song TS. Exogenous phosphatidylethanolamine induces apoptosis of human hematoma HepG2 cells via the bcl-2/ Bax pathway. World J Gastroenterology, 2009, 15(14):1751-8.

(33) Hu T*, Yao Y*, Yu S, Guo H, Han L, Wang W, Tian T, Hao Y, Liu Z, Nan K, Wang S. Clinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer. J Biomed Res. 2013 Jul;27(4):283-90

(34) Wang WJ*, Yao Y*, Jiang LL, Hu TH, Ma JQ, Liao ZJ, Yao JT, Li DF, Wang SH, Nan KJ. Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo. PLoS One. 2013 Oct 2;8(10):e76596.

联系方式
电子邮箱:13572101611@163.com
联系电话:13572101611
个人主页:
联系地址:5822yh银河国际第一附属医院肿瘤内科
更新日期:2022-09-30